NEW YORK, Oct. 29, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry, scientific and investor conferences in November: November 4-6: BIO-Europe. Members of Immunic's management, business development and investor relations teams will participate in partnering activities at this conference in Stockholm ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

– Based on a Review of Unblinded Data, an Independent Data Monitoring Committee (IDMC) Confirmed that Predetermined Futility Criteria Have Not Been Met –– IDMC Also Recommended Continuing Trial without Changes, Including no Need for a Potential Upsizing –– ENSURE Program Remains on Track to be Completed in 2026 –– Webcast to be Held Today, October 22, at 8:00 am ET –NEW YORK, Oct. 22, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administ ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

– Vidofludimus Calcium Consistently Reduced Neurofilament Light Chain Levels, Compared to Placebo, in the Interim Analysis of the Phase 2 CALLIPER Trial, Across Age and Disability Levels at Baseline For All Progressive Multiple Sclerosis Subtypes – – Clinical Signal Shown for Vidofludimus Calcium on Post COVID Fatigue May Be Related to Epstein-Barr Virus Reactivation; Preventing This Reactivation May Contribute to Fatigue Reduction in Multiple Sclerosis Patients – – Preclinical Data Showed Improved Neuronal ...

文章核心观点 - 公司的主要药物vidofludimus calcium正在进行针对post-COVID综合征(PCCS)的临床试验,该药物也正在进行多发性硬化症(MS)的III期临床试验 [1][2] - 该临床试验由德国研究人员发起,旨在探索vidofludimus calcium在治疗PCCS中的疗效,公司同意提供该药物用于试验 [2][3] - vidofludimus calcium是一种广谱抗病毒药物,可能有助于预防导致PCCS疲劳的病毒(如Epstein-Barr病毒)的复发 [4][5] - 该试验的结果可能为公司的MS项目提供支持,因为两种疾病中疲劳的机制可能相似 [6] - 公司期待2025年4月公布其MS进展性亚型的II期试验结果,如果成功将是一个重大进展 [7]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

文章核心观点 - 该研究旨在评估vidofludimus calcium对治疗COVID-19后综合征(PCS)及其相关症状(包括身体功能和疲劳)的疗效 [1][2][3] - vidofludimus calcium具有抗病毒和抗炎作用,可能有助于预防Epstein-Barr病毒(EBV)的再激活并减轻疲劳症状 [1][2] - EBV重新激活被认为是PCS患者疲劳的潜在原因之一 [1][2] - 疲劳也是多发性硬化症(MS)患者常见且令人衰弱的症状,目前尚无有效治疗方法,vidofludimus calcium可能对MS患者的疲劳症状产生积极影响 [1][2] 研究设计 - 这是一项由德国政府资助、由法兰克福大学(Goethe University Frankfurt)主导的随机、安慰剂对照、双盲、平行组临床2期试验 [3][4] - 计划在德国11个临床试验中心招募376名患者,随机1:1接受vidofludimus calcium(22.5 mg初始剂量7天,后45 mg 49天)或安慰剂 [4] - 主要终点为基线至第56天患者自身身体功能(SF-36-PF)的变化 [4] - 次要终点包括心理和身体健康、疲劳强度和丧失功能、精神障碍症状严重程度以及认知功能 [4] 关于vidofludimus calcium - vidofludimus calcium是一种小分子实验性药物,正在开发用于治疗多发性硬化症和其他慢性炎症性及自身免疫性疾病 [5] - 它通过激活神经保护性转录因子Nurr1,并选择性抑制二氢鼠李糖脱氢酶(DHODH)酶,发挥抗炎和抗病毒作用 [5] - 临床试验中,vidofludimus calcium已在1,800多名受试者中展现出良好的药代动力学、安全性和耐受性 [5]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

NEW YORK, Aug. 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will host a Multiple Sclerosis (MS) Research and Development (R&D) Day and participate in the following scientific and investor conferences in September: September 10: Immunic's MS R&D Day. Management of Immunic, including Daniel Vitt, Ph.D., Chief Execut ...